Table 2 Baseline characteristics of patient subgroups
| Measure | All patients eligible for the follow-up study, n = 172 | Patients with ≥ two MRIs in original trial and EDSS at 8-year follow-up, n = 138 | Patients with MRIs at all four time points, n = 106 |
|---|---|---|---|
| EDSS = Expanded Disability Status Scale; MSFC = MS Functional Composite; BPF = brain parenchymal fraction. | |||
| Age, y, mean (SD) | 36.1 (6.8) | 36.0 (6.9) | 35.9 (7.2) |
| Female, % | 77 | 76 | 77 |
| Disease duration, y, mean (SD) | 6.3 (5.6) | 6.1 (5.5) | 6.1 (5.1) |
| EDSS, mean (SD) | 2.3 (0.84) | 2.3 (0.84) | 2.3 (0.84) |
| MSFC, mean (SD) [no. of patients] | 0.0014 (0.71) [171] | 0.055 (0.65) [137] | 0.079 (0.59) [106] |
| T2 lesion volume, mL, mean (SD) [no. of patients] | 15.5 (15.7) [163] | 14.8 (15.3) [137] | 14.7 (15.4) [106] |
| T1 lesion volume, mL, mean (SD) [no. of patients] | 1.51 (2.03) [150] | 1.49 (2.02) [127] | 1.44 (1.44) [98] |
| Gadolinium + lesion number, mean (SD) [no. of patients] | 2.8 (6.7) [170] | 2.3 (5.1) [136] | 2.1 (4.9) [104] |
| BPF, mean (SD) [no. of patients] | 0.830 (0.017) [137] | 0.830 (0.018) [127] | 0.832 (0.016) [106] |